fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

European Commission approval for Verquvo to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction – Bayer + Merck Inc.

Written by | 31 Jul 2021 | Cardiology

Merck Inc., has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat).

In the EU, Verquvo (2.5 mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy.

Verquvo is being jointly developed by Merck and Bayer AG. Merck Inc., has the commercial rights to Verquvo in the United States and Bayer has the exclusive commercial rights in the rest of world.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.